This article is more than 5 years old. Information may no longer be current.
CMS classifies CGM as ‘durable medical equipment’
Click Here to Manage Email Alerts
The CMS recently announced that continuous glucose monitoring devices will be categorized as “durable medical equipment,” according to a press release from the American Association of Clinical Endocrinologists and the American College of Endocrinology.
AACE and ACE are commending the ruling after a 2014 consensus conference on glucose monitoring determined that “glucose monitoring is essential to diabetes care, particularly for reducing hypoglycemia, provided it is structured.”
“AACE has actively worked to achieve this goal for several years,” Pauline Camacho, MD, FACE, president of AACE, said in the release. “We are pleased our persistence had paid off and more of our patients will soon have access to this beneficial technology.”
The JDRF, formerly the Juvenile Diabetes Research Foundation, also commends the ruling that will make Medicare funding more possible, according to a release from the organization.
“JDRF is encouraged by this decision, which will bring us one step closer to Medicare coverage for [continuous glucose monitors],” Aaron J. Kowalski, PhD, chief mission officer of JDRF, said in the release. “We want to thank the tireless JDRF advocates and congressional champions who have made this progress possible.”
Dexcom’s G5 Mobile is the first continuous glucose monitoring (CGM) device that falls within the classification.
“This landmark CMS ruling will make available the most important technology in diabetes management to the Medicare population,” Kevin Sayer, president and CEO of Dexcom, said in a company press release. “We are pleased with this important step forward and we look forward to Medicare on implementing coverage in the coming months to ensure beneficiaries have access to this life-saving device.”
For more information, please see the full ruling.